XML 33 R29.htm IDEA: XBRL DOCUMENT v3.20.1

CO-DEVELOPMENT AND LICENSE AGREEMENT - Additional Information (Details) - USD ($) $ / shares in Units, shares in Millions				1 Months Ended		3 Months Ended		12 Months Ended
	Aug. 29, 2017	Jul. 06, 2016	Jul. 07, 2014	Apr. 30, 2020	Jan. 31, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Co-development and license agreement
Research and development expense						$ 8,082,510	$ 11,606,197
Phase 3 Insomnia Trail
Co-development and license agreement
Percentage of milestone payment on aggregate product development cost						40.00%
Janssen | Phase 3 Insomnia Trail
Co-development and license agreement
Milestone method payments						$ 40,000,000
Percentage of milestone payment on aggregate product development cost						40.00%
Development cost invoiced					$ 3,400,000	$ 6,500,000
Janssen | Phase 3 Insomnia Trail | Forecast
Co-development and license agreement
Estimated development costs								$ 100,000,000
Janssen | Phase 3 Insomnia Trail | Subsequent Event
Co-development and license agreement
Development cost invoiced				$ 3,100,000
Janssen | Seltorexant | Co-Development and License Agreement
Co-development and license agreement
Payment of license fee			$ 22,000,000
Payment of development costs		$ 3,500,000
Direct expenses incurred		$ 300,000
Research and development expense						$ 0	$ 0
Janssen | Seltorexant | Amendment to Co-Development and License Agreement
Co-development and license agreement
Upfront payment	$ 30,000,000
Revenue recognition, milestone method, factors						The $30 million payment and $11.2 million in previously accrued collaborative expenses, which were forgiven upon the effective date of the Amendment, are earned and recognized as revenue as the services are performed from the commencement of Phase 3 development to the completion of the development activities using the proportional performance method.
Accrued collaborative expenses	11,200,000
Upfront payment received						$ 30,000,000			$ 30,000,000
Previously accrued collaborative expenses recognized as revenue						$ 11,200,000			$ 11,200,000
Janssen | Seltorexant | Amendment to Co-Development and License Agreement | Phase 3 Insomnia Trail
Co-development and license agreement
Payment start of Phase	20,000,000
Payment upon enrollment of patients	$ 20,000,000
Percentage of patients to be enrolled	50.00%
Johnson & Johnson Innovation-JJDC Inc
Co-development and license agreement
Stock repurchased	3.9
Stock repurchased price per share	$ 0.0001
Aggregate purchase price	$ 389

X

- Definition

Accrued research and development costs current.

+ References

No definition available.

+ Details

Name:	nerv_AccruedResearchAndDevelopmentCostsCurrent
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Contract with customer liability milestone method factors.

+ References

No definition available.

+ Details

Name:	nerv_ContractWithCustomerLiabilityMilestoneMethodFactors
Namespace Prefix:	nerv_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Development cost invoiced.

+ References

No definition available.

+ Details

Name:	nerv_DevelopmentCostInvoiced
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Direct expenses incurred, development costs.

+ References

No definition available.

+ Details

Name:	nerv_DirectExpensesIncurredDevelopmentCosts
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Estimated development costs.

+ References

No definition available.

+ Details

Name:	nerv_EstimatedDevelopmentCosts
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Payment of license fee.

+ References

No definition available.

+ Details

Name:	nerv_PaymentOfLicenseFee
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Payments for development cost.

+ References

No definition available.

+ Details

Name:	nerv_PaymentsForDevelopmentCost
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Percentage of milestone payment on aggregate product development cost.

+ References

No definition available.

+ Details

Name:	nerv_PercentageOfMilestonePaymentOnAggregateProductDevelopmentCost
Namespace Prefix:	nerv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage of patients to be enrolled.

+ References

No definition available.

+ Details

Name:	nerv_PercentageOfPatientsToBeEnrolled
Namespace Prefix:	nerv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Product development cost payable.

+ References

No definition available.

+ Details

Name:	nerv_ProductDevelopmentCostPayable
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Product development cost payable upon enrollment of patients.

+ References

No definition available.

+ Details

Name:	nerv_ProductDevelopmentCostPayableUponEnrollmentOfPatients
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Revenue recognition milestone method revenue expected.

+ References

No definition available.

+ Details

Name:	nerv_RevenueRecognitionMilestoneMethodRevenueExpected
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Stock repurchased price per share.

+ References

No definition available.

+ Details

Name:	nerv_StockRepurchasedPricePerShare
Namespace Prefix:	nerv_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Upfront payment paid.

+ References

No definition available.

+ Details

Name:	nerv_UpfrontPaymentPaid
Namespace Prefix:	nerv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12A
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL108322424-203045

+ Details

Name:	us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockRepurchasedDuringPeriodShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockRepurchasedDuringPeriodValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nerv_PhaseThreeClinicalTrialsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=nerv_JanssenPharmaceuticaNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=nerv_SeltorexantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=nerv_AmendmentToCoDevelopmentAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=nerv_JohnsonAndJohnsonInnovationJJDCIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: